Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Idelalisib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Calluna Completes Phase 1 Study of CAL101 for Fibrotic Inflammatory Diseases
Details : CAL101 is a first-in-class mAb that targets S100A4, a DAMP protein implicated in serious and life-threatening diseases, such as idiopathic pulmonary fibrosis and systemic sclerosis.
Product Name : CAL101
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
October 23, 2024
Lead Product(s) : Idelalisib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Idelalisib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Forbion
Deal Size : $81.1 million
Deal Type : Series A Financing
Two biotechs Merge to Form Calluna, with €75M in Hand to Focus on Immunotherapy Antibodies
Details : Calluna Pharma focuses on the clinical stage lead program CAL101, which is a monoclonal antibody that neutralizes the bioactivity of S100A4 & implements DAMP protein for idiopathic pulmonary fibrosis.
Product Name : CAL101
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
January 22, 2024
Lead Product(s) : Idelalisib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Forbion
Deal Size : $81.1 million
Deal Type : Series A Financing
Reset All
